Condition
Obesity
Locations
United States
Start date
26/09/2025
Identifiers
Trial ID NN9838-8215,
NCT number NCT07184086,
Eudract number Not Available
NCT number NCT07184086,
Eudract number Not Available
Summary
In this study we will be looking into how CagriSema influences metabolism (the process by which food is used to supply energy for the body) compared to a diet. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors but has previously been tested in humans. The study is split into 2 parts. In the first part of the study, participants will either get CagriSema or a weight loss diet (calorie reduced). In the second part of the study,all participants will get CagriSema. Which treatment participants get in the first part of the study is decided by chance. Like all medicines, the study medicine may have side effects. The study will last for about 1.5 years.
Trial Overview:
Treatment
DRUG: CagriSema (Cagrilintide B + semaglutide I)
BEHAVIORAL: Low Energy Diet
Study type
INTERVENTIONAL
Trial duration
Sep 26 2025 - Oct 12 2027
Participants
80
Phase
I
Are you eligible?
Gender
Male and female
Age
18 to 65 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.